Most of the assays met the proposed goals for precision (86% of intra-assay results and 75% of inter-assay results). Results: All evaluated assays except total thyroxine were within the proposed goals for trueness. Data were provided by Beckman Coulter, Inc. Local data were collected for precision, linearity, and consistency. Methods: Clinically oriented performance goals were defined using the following methods: trueness-published desirable accuracy limits, precision-published desirable biologic variation detection limits - 0.1 percentile of patient test values, linearity - 50% of total error, and consistency-percentage test values crossing key decision points. Conclusions: The Beckman Coulter DxI 800 immunoassay system meets most of these proposed goals, even though these clinically focused performance goals represent relatively stringent limits.Ībstract = "Objectives: We evaluated the analytical performance of 24 immunoassays using the Beckman Coulter DxI 800 immunoassay systems at Mayo Clinic, Rochester, MN for trueness, precision, detection limits, linearity, and consistency (across instruments and reagent lots). Lot-to-lot consistency results for cortisol, ferritin and total thyroxine exceeded the proposed goals of 3.3%, 11.4% and 7% at one medical decision level, while vitamin B12 exceeded the proposed goals of 5.2% and 3.8% at two decision levels. All evaluated assays were within the proposed goals for instrument consistency.
#Beckman coulter dxi free#
Carcinoembryonic antigen, total thyroxine and free triiodothyronine exceeded the proposed goals of ±. Five assays had more than 15% of the test results below the minimum detection limits.
![beckman coulter dxi beckman coulter dxi](https://41g5tbxsk2jmqyak1xtj8cbp-wpengine.netdna-ssl.com/wp-content/uploads/2021/02/IMG_3455-scaled.jpeg)
All rights reserved.Objectives: We evaluated the analytical performance of 24 immunoassays using the Beckman Coulter DxI 800 immunoassay systems at Mayo Clinic, Rochester, MN for trueness, precision, detection limits, linearity, and consistency (across instruments and reagent lots). The Beckman Coulter DxI 800 immunoassay system meets most of these proposed goals, even though these clinically focused performance goals represent relatively stringent limits.Īnalytical performance Beckman Coulter DxI 800 Immunoassay Precision Quality control.Ĭopyright © 2014 The Canadian Society of Clinical Chemists. Carcinoembryonic antigen, total thyroxine and free triiodothyronine exceeded the proposed goals of ☖.3%, ±5% and ±5.7% for dilution linearity. for trueness and detection limits.Īll evaluated assays except total thyroxine were within the proposed goals for trueness.
![beckman coulter dxi beckman coulter dxi](https://cdn.caeonline.com/images/beckman-coulter_unicel-dxi-800_1272145.jpg)
![beckman coulter dxi beckman coulter dxi](https://healthcare-in-europe.com/media/product/1964/content_img-01-image-01-beckmancoulter-dxc700-au-chemistry-analyzer-original.jpg)
We evaluated the analytical performance of 24 immunoassays using the Beckman Coulter DxI 800 immunoassay systems at Mayo Clinic, Rochester, MN for trueness, precision, detection limits, linearity, and consistency (across instruments and reagent lots).Ĭlinically oriented performance goals were defined using the following methods: trueness-published desirable accuracy limits, precision-published desirable biologic variation detection limits - 0.1 percentile of patient test values, linearity - 50% of total error, and consistency-percentage test values crossing key decision points.